Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114029 | 0.88 | SMN1; SMN2 (0.52) | ACE2PREPRAB9ACTRB1FKBP1A | |
| SCHEMBL3098746 | 0.88 | SMN1; SMN2 (0.52) | ACE2PREPRAB9ACTRB1FKBP1A | |
| SCHEMBL2721261 | 0.88 | SMN1; SMN2 (0.52) | ACE2PREPRAB9ACTRB1FKBP1A | |
| SCHEMBL1488515 | 0.86 | FKBP1A (0.50) | PREPRAB9AFKBP1ASMN1; SMN2NPC1 | |
| SCHEMBL1488503 | 0.86 | FKBP1A (0.50) | PREPRAB9AFKBP1ASMN1; SMN2NPC1 | |
| SCHEMBL1488666 | 0.86 | FKBP1A (0.50) | PREPRAB9AFKBP1ASMN1; SMN2NPC1 | |
| SCHEMBL20135734 | 0.78 | MEN1 (0.61) | RAB9ASMN1; SMN2NPC1CYP2C19TMEM97 | |
| SCHEMBL28449948 | 0.75 | RAB9A (0.51) | ACE2RAB9ASMN1; SMN2 | |
| SCHEMBL18089695 | 0.73 | SMN1; SMN2 (0.50) | ACE2PREPRAB9ACTRB1SMN1; SMN2 | |
| SCHEMBL13119286 | 0.73 | PREP (0.61) | PREPCTRB1FKBP1ACTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |